In type 1 diabetes, beta cells are attacked and destroyed by auto reactive T cells causing major impairment of blood glucose metabolism and, ultimately, the development of life-threatening complications. Currently, the treatment of this chronic disease is based on the use of endogenous insulin and no curative therapies are available. Treatment approaches in this respect need to be directed toward the primary causes of the disease tackling beta cells' auto reactive T cells. The goal of any curative intervention in type 1 diabetes is the preservation of insulin-secreting cells. This may be achieved by the abrogation of the pathogenic reactivity to beta cell auto antigens while preserving full capacity to generate a normal immune response against foreign antigens. In this review, some of the most promising drugs for immune intervention in type 1 diabetes are presented and discussed including phase 3 clinical trials that involve: DiaPep277, Anti-CD3 Otelixizumab, Glutamic Acid Decarboxylase ( GAD) and anti-IL1 receptor antagonist. These approaches are currently being tested in international multicenter trials and all of them have a very similar outcome in terms of a beneficial effect on beta cells.

Clinical Update on the Use of Immuno Modulators (antiCD3, GAD, Diapep277, Anti-IL1) in Type 1 Diabetes / Paolo, Pozzilli; Chiara, Guglielmi; Daria, Maggi; Carlone, Angela; Buzzetti, Raffaella; Silvia, Manfrini. - In: CURRENT PHARMACEUTICAL DESIGN. - ISSN 1381-6128. - 17:29(2011), pp. 3224-3228. [10.2174/138161211798157531]

Clinical Update on the Use of Immuno Modulators (antiCD3, GAD, Diapep277, Anti-IL1) in Type 1 Diabetes

CARLONE, ANGELA;BUZZETTI, Raffaella;
2011

Abstract

In type 1 diabetes, beta cells are attacked and destroyed by auto reactive T cells causing major impairment of blood glucose metabolism and, ultimately, the development of life-threatening complications. Currently, the treatment of this chronic disease is based on the use of endogenous insulin and no curative therapies are available. Treatment approaches in this respect need to be directed toward the primary causes of the disease tackling beta cells' auto reactive T cells. The goal of any curative intervention in type 1 diabetes is the preservation of insulin-secreting cells. This may be achieved by the abrogation of the pathogenic reactivity to beta cell auto antigens while preserving full capacity to generate a normal immune response against foreign antigens. In this review, some of the most promising drugs for immune intervention in type 1 diabetes are presented and discussed including phase 3 clinical trials that involve: DiaPep277, Anti-CD3 Otelixizumab, Glutamic Acid Decarboxylase ( GAD) and anti-IL1 receptor antagonist. These approaches are currently being tested in international multicenter trials and all of them have a very similar outcome in terms of a beneficial effect on beta cells.
2011
anti-cd3; anti-il1 receptor antagonist; autoimmunity; diapep 277; gad; immuno intervention; immuno tolerance; type 1 diabetes
01 Pubblicazione su rivista::01a Articolo in rivista
Clinical Update on the Use of Immuno Modulators (antiCD3, GAD, Diapep277, Anti-IL1) in Type 1 Diabetes / Paolo, Pozzilli; Chiara, Guglielmi; Daria, Maggi; Carlone, Angela; Buzzetti, Raffaella; Silvia, Manfrini. - In: CURRENT PHARMACEUTICAL DESIGN. - ISSN 1381-6128. - 17:29(2011), pp. 3224-3228. [10.2174/138161211798157531]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/384814
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 11
social impact